相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
Powder: -20°C, 3 years. In solvent: -80°C, 6 months; -20°C, 1 month.
- 库存:
货期:1-2天
- 供应商:
MedChemExpress LLC
- CAS号:
129-20-4
- 规格:
10 mM * 1 mL/5 mg/10 mg/25 mg/50 mg
| 规格: | 10 mM * 1 mL | 产品价格: | ¥1320.0 |
|---|---|---|---|
| 规格: | 5 mg | 产品价格: | ¥750.0 |
| 规格: | 10 mg | 产品价格: | ¥1200.0 |
| 规格: | 25 mg | 产品价格: | ¥2300.0 |
| 规格: | 50 mg | 产品价格: | ¥3700.0 |
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
Oxyphenbutazone
CAS No. : 129-20-4
MCE 国际站:Oxyphenbutazone
产品活性:Oxyphenbutazone 是一种保泰松 (Phenylbutazone; HY-B0230) 代谢物,具有抗炎作用。Oxyphenbutazone 是一种具有口服活性的非选择性 COX 抑制剂。Oxyphenbutazone 能选择性地杀死不复制的结核分枝杆菌 (Mycobaterium tuberculosis)。
研究领域:Immunology/Inflammation | Anti-infection
In Vitro: Oxyphenbutazone enhances the anticancer efficiency of Methotrexate (MTX) (HY-14519) in Hep3B cells.
Oxyphenbutazone (2.5-7.5 µM; 48 hours) co-treatment with (MTX, 0.25-1.0 µM) shows potential cytotoxicity against Hep3B cells.
Oxyphenbutazone exhibits reparative effects in the hepatocytes.
In Vivo: Oxyphenbutazone (70 mg/kg/week; p.o.; in two divided doses; for 13 weeks) exerts potential anticancer activity when co-treatment with MTX (5.0 or 2.5 mg/kg/week; i.p.).
相关产品:Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Anti-Infection Compound Library | Immunology/Inflammation Compound Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Antibacterial Compound Library | Orally Active Compound Library | Traditional Chinese Medicine Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Drug-Induced Liver Injury (DILI) Compound Library | Anti-inflammatory Traditional Chinese Medicine Active Compound Library | Human Metabolite Library | Non-steroidal Anti-Inflammatory Compound Library | Heterocyclic Compound Library | Withdrawn Drug Compound Library | Off-patent Drug Library | Anti-tuberculosis Compound Library | Highly Selective Inhibitors Library | FDA-Approved Traditional Chinese Medicine Active Compound Library | Rapamycin | Doxorubicin hydrochloride | Bafilomycin A1 | Dexamethasone | Puromycin dihydrochloride | Dimethyl sulfoxide | Staurosporine | Actinomycin D | G-418 disulfate | Etoposide | 5-Azacytidine | Nigericin sodium salt | Brefeldin A | Estradiol | CCCP | Ionomycin | Resveratrol | Hygromycin B | Tunicamycin | Mitomycin C | Everolimus | Doxycycline hyclate | Tacrolimus | Methotrexate | Neomycin sulfate | Acetaminophen | Streptozotocin | Anisomycin | Cholesterol
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验佚名 吡唑酮类药物包括保泰松(phenylbutazone;布他酮,butazolidin)及其化谢产物羟基保泰松(oxyphenbutazone)。 保泰松及羟基保泰松 【体内过程】口服保泰松吸收迅速完全,2小时达峰血药浓度值,吸收后98%与血浆蛋白结合,再缓慢释出,故作用持久,血浆t 1/2 为50~65
网络 第三节 吡唑酮类 本类药物包括保泰松(phenylbutazone;布他酮,butazolidin)及其化谢产物羟基保泰松(oxyphenbutazone)。 保泰松及羟基保泰松 【体内过程】口服保泰松吸收迅速完全,2小时达峰血药浓度值,吸收后98%与血浆蛋白结合,再缓慢释出,故作用持久,血浆t
氨基酚(paracetamol)0.5g/次,3次/日。 保泰松(phenylbutazone) 0.1~0.2g/次,3次/日。症状改善后改为1次/日。 羟基保泰松(oxyphenbutazone)0.1g/次,3次/日。餐中服,一周后递减,0.1~0.2g/日。 吲哚美辛(indomethacin)25mg/次,2~3次/日。餐中服,以后每周可递增25mg至每日总量为100~150mg。 舒林酸(sulindac)150~200mg/次,2次/日。每日最大剂量400mg。
技术资料暂无技术资料 索取技术资料

















